Disclosures for "Addition of optic nerve involvement to dissemination in space criteria for multiple sclerosis – the value of optical coherence tomography")
-
Dr. Bsteh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Bsteh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Celgene-BMS. Dr. Bsteh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Bsteh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Bsteh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Bsteh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi Genzyme.
-
Dr. Hegen has nothing to disclose.
-
The institution of Mr. Altmann has received research support from Quanterix. The institution of Mr. Altmann has received research support from Biogen, Merck, Roche, Sanofi, Teva,. Mr. Altmann has received intellectual property interests from a discovery or technology relating to health care.
-
Michael Auer has nothing to disclose.
-
Dr. Berek has nothing to disclose.
-
Franziska Di Pauli has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Franziska Di Pauli has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Franziska Di Pauli has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jannsen. Franziska Di Pauli has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Franziska Di Pauli has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Franziska Di Pauli has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Franziska Di Pauli has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Franziska Di Pauli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for horizon. Franziska Di Pauli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Franziska Di Pauli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for merck. Franziska Di Pauli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Jannsen. Franziska Di Pauli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. The institution of Franziska Di Pauli has received research support from Roche.
-
Dr. Kornek has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Kornek has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS Celgene. Dr. Kornek has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Johnson&Johnson. Dr. Kornek has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Kornek has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Kornek has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi-Genzyme. The institution of Dr. Kornek has received research support from Novartis.
-
Nik Krajnc has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi-Genzyme. Nik Krajnc has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BMS/Celgene. The institution of Nik Krajnc has received research support from ECTRIMS.
-
Fritz Leutmezer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Almirall, Biogen, Celgene, Johnson&Johnson, Novartis, Merck, Roche, Sanofi, Teva-Ratiopharm. Fritz Leutmezer has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Almirall, Biogen, Celgene, Johnson&Johnson, Novartis, Merck, Roche, Sanofi, Teva-Ratiopharm. Fritz Leutmezer has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Almirall, Biogen, Celgene, Johnson&Johnson, Novartis, Merck, Roche, Sanofi, Teva-Ratiopharm. The institution of Fritz Leutmezer has received research support from Biogen, Merck, Novartis, Roche.
-
Dr. Macher has nothing to disclose.
-
Dr. Rommer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Rommer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Rommer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for biogen. The institution of Dr. Rommer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for celgene. The institution of Dr. Rommer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for merck. Dr. Rommer has received personal compensation in the range of $0-$499 for serving as a Consultant for sanofi. Dr. Rommer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for sandoz. Dr. Rommer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. Dr. Rommer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for almirall. Dr. Rommer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for biogen. Dr. Rommer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Rommer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. The institution of Dr. Rommer has received research support from merck. The institution of Dr. Rommer has received research support from roche. The institution of Dr. Rommer has received research support from amicus. The institution of Dr. Rommer has received research support from biogen.
-
Karin Zebenholzer has nothing to disclose.
-
Gudrun Zulehner has nothing to disclose.
-
Tobias Zrzavy has nothing to disclose.
-
Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Almirall. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Deisenhammer has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS/Celgene. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi/Genzyme. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Almirall. Dr. Deisenhammer has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Celgene. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Genzyme. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Dr. Deisenhammer has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Novartis. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Deisenhammer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for SOBI.
-
Dr. Pemp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Chiesi. Dr. Pemp has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Chiesi. Dr. Pemp has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GenSight. The institution of Dr. Pemp has received research support from Chiesi.
-
Prof. Berger has received personal compensation in the range of $10,000-$49,999 for serving as a speaker at scientific meetings and participant of local and international advisory boards with various companies producing and markerting treatments for multiple sclerosis (Almirall, Biogen, Biologix, Bionorica, Celgene-BMS, Merck, Novartis, Roche, Sanofi-Genzyme, TG Therapeutics, UCB).